Chimeric antigen receptors (CARs) are recombinant receptors that are expressed on autologous T-cells. CAR-T usage has grown in recent years as a way to combat hematological and solid tumors. The purpose of this review is to describe new studies on CAR-T treatment along with our lab’s ideas on potential uses and pitfalls that could be investigated. The usage of TREG and antiCLTA4 as means for regulating CAR-T will also be looked at along with OX40, CD137 and CD27 receptors as means for increasing the efficacy of the treatment overall. In addition the usage of iCasp9 as a ‘suicide switch’ for the CAR-T treatment and the potential for a 4th generation CAR will be touched upon. Then the review will lead into talks about how such a treatment could be of potential use in treating solid and hematological cancer.